BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?
bioAffinity Technologies is surging Wednesday as traders digest recent commercial expansion news alongside tight low-float trading dynamics.
Stocks · News reference
bioAffinity stock trades higher as it advances its CyPath Lung test for post-treatment lung cancer surveillance.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
bioAffinity Technologies is surging Wednesday as traders digest recent commercial expansion news alongside tight low-float trading dynamics.
U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday.The Dow traded down 0.40% to 52,971.81 while the NASDAQ dipped 0.52% to 26,232.46. The S&P 500 also